Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports

Clinical Therapeutics

Volumn 28, Issue 8, 2006, Pages 1123-1132

  Sanchez Matienzo, David ^a   Arana, Alejandro ^a   Castellsague, Jordi ^a   Perez Gutthann, Susana ^a  

^a PFIZER INC   (United States)

Author keywords

case noncase study; hepatotoxicity; NSAIDs

Indexed keywords

ALLOPURINOL; AMIODARONE; AMOXICILLIN; AMPICILLIN; BROMFENAC; BUSULFAN; CAPTOPRIL; CARBAMAZEPINE; CEFALEXIN; CELECOXIB; CHLORPROMAZINE; CIMETIDINE; CLOXACILLIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DICLOFENAC; ERYTHROMYCIN; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOROLAC; MELOXICAM; MINOCYCLINE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; UNINDEXED DRUG;

ARTICLE; DATA BASE; DRUG EXPOSURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; PREVALENCE; WORLD HEALTH ORGANIZATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPHENONES; BROMOBENZENES; CYCLOOXYGENASE 2 INHIBITORS; DRUG-INDUCED LIVER INJURY; HUMANS; LACTONES; LIVER DISEASES; ODDS RATIO; PYRAZOLES; SAFETY; SULFONAMIDES; SULFONES; SULINDAC;

EID: 33748625434     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.08.014     Document Type: Article

References (44)

1. Garcia Rodriguez L.A., Williams R., Derby L.E., et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 154 (1994) 311-316
2. Garcia Rodriguez L.A., Ruigomez A., and Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy 17 (1997) 721-728
3. [published correction appears in BMJ. 1992;305:920]. Garcia Rodriguez L.A., Perez Gutthann S., Walker A.M., and Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 305 (1992) 865-868
4. Fontana R.J., McCashland T.M., Benner K.G., et al., Acute Liver Failure Study Group. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transpl Surg 5 (1999) 480-484
5. Moses P.L., Schroeder B., Alkhatib O., et al. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 94 (1999) 1393-1396
6. Macia M.A., Carvajal A., del Pozo J.G., et al. Hepatotoxicity associated with nimesulide: Data from the Spanish Pharmacovigilance System. Clin Pharmacol Ther 72 (2002) 596-597
7. Merlani G., Fox M., Oehen H.P., et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 57 (2001) 321-326
8. Boelsterli U.A. Mechanisms of NSAID-induced hepatotoxicity: Focus on nimesulide. Drug Saf 25 (2002) 633-648
9. Traversa G., Bianchi C., Da Cas R., et al. Cohort study of hepatotoxicity associated with nimesulide and other nonsteroidal anti-inflammatory drugs. BMJ 327 (2003) 18-22
10. Tarazi E.M., Harter J.G., Zimmerman H.J., et al. Sulindac-associated hepatic injury: Analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 104 (1993) 569-574
11. Perez Gutthann S., and Garcia Rodriguez L.A. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 4 (1993) 496-501
12. Manoukian A.V., and Carson J.L. Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf 15 (1996) 64-71
13. [published correction appears in Am J Ther. 2000;7:341]. Maddrey W.C., Maurath C.J., Verburg K.M., and Geis G.S. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 7 (2000) 153-158
14. McCormick P.A., Kennedy F., Curry M., and Traynor O. COX 2 inhibitor and fulminant hepatic failure. Lancet 353 (1999) 40-41
15. Alegria P., Lebre L., and Chagas C. Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis. Ann Intern Med 137 (2002) 75
16. Harsch I.A., Michaeli P., Hahn E.G., et al. A rare case of rofecoxib-induced cholestatic hepatitis. Dig Liver Dis 35 (2003) 911-912
17. Huster D., Schubert C., Berr F., et al. Rofecoxib-induced cholestatic hepatitis: Treatment with molecular adsorbent recycling system (MARS). J Hepatol 37 (2002) 413-414
18. (Suppl). Sanchez-Matienzo D., Castellsague J., and Arana A. Effect of control of confounding in the estimation of the Proportional Reporting Ratio. Pharmacoepidemiol Drug Saf 13 (2004) S2-S225
19. Arana A., Arellano F.M., Sanchez-Matienzo D., and Perez-Gutthann S. Choosing the measure of relative proportional reporting in quantitative analyses of spontaneous reports. Pharmacoepidemiol Drug Saf 13 (2004) S324
20. Egberts A.C., Meyboom R.H., and van Puijenbroek E.P. Use of measures of disproportionality in pharmacovigi lance: Three Dutch examples. Drug Saf 25 (2002) 453-458
21. van Puijenbroek E.P., Egberts A.C., Meyboom R.H., and Leufkens H.G. Association between terbinafine and arthralgia, fever and urticaria: Symptoms or syndrome?. Pharmacoepidemiol Drug Saf 10 (2001) 135-142
22. Derijks J., Koning F., Meyboom R., et al. The association between antidepressant use and hypoglycemia and hyperglycemia. Pharmacoepidemiol Drug Saf 13 (2004) 521
23. [CIDER Web site]. US Food and Drug Administration, Center for Drug Evaluation and Research. Spontaneous reporting system. Accessed June 15 (2006-2006), FDA, Washington, DC. http://www.fda.gov/cder/handbook/adverse.htm Accessed June 15
24. [CIDER Web site]. Available at. US Food and Drug Administration. Center for Drug Evaluation and Research. Accessed June 15 (2006). http://www.fda.gov/cder/index.html
25. Avail able at. US Food and Drug Administration. MedWatch: The FDA Medical Products Reporting Program. Accessed July 15 (2006). http://www.fda.gov/medwatch
26. March. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CIDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry E2B(M): Data Elements for Transmission of Individual Case Safety Reports (2005)
27. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (2003), Northrop Grumman MSSO, Reston, Va
28. US Food and Drug Administration. Center for Drug Evaluation and Research. The Adverse Event Reporting System (AERS) Older Quarterly Data Files. [CIDER Web site]. Available at (2006). http://www.fda.gov/CIDER/aers/aers/prev Accessed June 15
29. [WHO Web site]. Available at. World Health Organization. WHO Programme for International Drug Monitoring. Accessed June 15 (2006). http://www.whoumc.org/DynPage.aspx?id=13140&mn=1514
30. [WHO Web site]. World Health Organization. Adverse Reaction Terminology. Accessed June 15 (2001-2006), WHO/UMC, Uppsala, Sweden. http://www.umcproducts.com/DynPage.aspx?id=2829&mn=1107 Accessed June 15
31. [MedDRA Web site]. World Health Organization, Council for International Organizations of Medical Sciences. Development and Rational Use of Standardised MedDRA Queries (SMQs): Retrieving Adverse Drug Reactions with MedDRA. Accessed June 15 (2005-2006), WHO, Geneva. Switzerland. http://www.meddramsso.com/MSSOWeb/SMQ/index.htm Accessed June 15
32. Stricker B.H. Drug-Induced Hepatic Injury. 2nd ed. (1992), Elsevier, New York, NY
33. van Puijenbroek E.P., Bate A., Leufkens H.G., et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11 (2002) 3-10
34. Hernandez-Diaz S., and Garcia-Rodriguez L.A. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 110 Suppl 3A (2001) 20S-27S
35. de Abajo F.J., Montero D., Madurga M., and Garcia Rodriguez L.A. Acute and clinically relevant drug-induced liver injury: A population based casecontrol study. Br J Clin Pharmacol 58 (2004) 71-80
36. Lucena M.I., Camargo R., Andrade R.J., et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33 (2001) 123-130
37. PhRMA/FDA/AASLD Drug-induced hepatotoxicity white paper postmarketing considerations (2000). http://www.fda.gov/cder/livertox/postmarket.pdf
38. Aithal G.P., Rawlins M.D., and Day C.P. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 319 (1999) 1541
39. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 36 (2002) 451-455
40. Hennessy S. Disproportionality analyses of spontaneous reports. Pharmacoepidemiol Drug Saf 13 (2004) 503-504
41. discussion 527-528. Waller P., van Puijenbroek E., Egberts A., and Evans S. The reporting odds ratio versus the proportional reporting ratio: 'Deuce'. Pharmacoepidemiol Drug Saf 13 (2004) 525-526
42. Rothman K.J., Lanes S., and Sacks S.T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13 (2004) 519-523
43. Mann R.D. Assessments of disproportionality. Pharmacoepidemiol Drug Saf 13 (2004) 501-502
44. Goldkind L., and Lame L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: Lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 15 (2006) 213-220